Shield Therapeutics plc (STX) · 2026-08-20
Shield Therapeutics reported H1 2026 revenue of $30.4 million, up 42%, and a $0.2 million operating profit versus a $5.8 million loss. Cash fell to $8.3 million from $11.6 million, while $24.9 million was due to Runway Growth Capital.
Shield Therapeutics plc (STX) · 2026-07-30
Shield Therapeutics reported Q2 US ACCRUFeR revenue of $10.3M versus $12.8M, while H1 revenue rose to $30.4M, including a $7.9M ASK China milestone.
Shield Therapeutics plc (STX) · 2026-07-28
Shield Therapeutics published positive Phase 3 FORTIS results for ferric maltol in Pediatric Drugs, including improved haemoglobin and iron storage within 12 weeks in children aged 1 month and above.